Disclosure of Amyloid Status for Risk of Alzheimer Disease to Cognitively Normal Research Participants With Subjective Cognitive Decline: A Longitudinal Study
Disclosure of Amyloid Status for Risk of Alzheimer Disease to Cognitively Normal Research Participants With Subjective Cognitive Decline: A Longitudinal Study
复制标题
DOI：
10.1177/1533317520904551
复制
发表时间：
2020-01-01
影响因子：
3.4
通讯作者：
Mimura, Masaru
中科院分区：
文献类型：
--
作者：
Wake, Taisei;Tabuchi, Hajime;Mimura, Masaru
本研究旨在调查披露淀粉样蛋白状态对阿尔茨海默病（AD）风险的长期影响，以认知正常的研究参与者主观认知下降（SCD），这是AD的初始表现。42名参与者被分为淀粉样蛋白阳性（n = 10）或淀粉样蛋白阴性（n = 32）组。我们在结果公布后的第6周、第24周和第52周评估了焦虑、抑郁和与考试相关的痛苦症状。随着时间的推移，两组的焦虑、抑郁和考试相关的痛苦没有差异。虽然两组之间在焦虑或抑郁方面没有显著差异，但在52周时，淀粉样蛋白阴性组的测试相关痛苦水平显著高于淀粉样蛋白阳性组。向患有SCD的认知健康的研究参与者披露淀粉样蛋白状态不会导致显著的长期心理风险。然而，在淀粉样蛋白阴性个体中，可能存在关于认知能力下降的主观担忧的理论谱。
This study aimed to investigate the long-term impacts of disclosing amyloid status for a risk of Alzheimer disease (AD) to cognitively normal research participants with subjective cognitive decline (SCD), which represents an initial manifestation of AD. Forty-two participants were classified as the amyloid-positive (n = 10) or amyloid-negative (n = 32) groups. We assessed symptoms of anxiety, depression, and test-related distress at 6, 24, and 52 weeks after results disclosure. No difference was found over time in anxiety, depression, and test-related distress in either group. Although no significant differences were observed between groups in anxiety or depression, the amyloid-negative group had a significantly higher level of test-related distress than the amyloid-positive group at 52 weeks. Disclosing amyloid status to cognitively healthy research participants with SCD did not cause significant long-term psychological risks. However, a theoretical spectrum of subjective concern may exist about cognitive decline in amyloid-negative individuals.